Company Valuation: Vertex Pharmaceuticals Incorporated

Data adjusted to current consolidation scope
Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028
Market Cap 1 55,834 74,127 104,849 103,707 115,026 114,329 - -
Change - 32.76% 41.44% -1.09% 10.91% -0.61% - -
Enterprise Value (EV) 1 48,309 63,349 93,630 97,591 108,418 101,545 97,195 92,828
Change - 31.13% 47.8% 4.23% 11.09% -6.34% -4.28% -4.49%
P/E Ratio 24.4x 22.5x 29.3x -194x 29.6x 25.8x 22.9x 19.6x
PBR 5.53x 5.33x 5.96x 6.4x 6.17x 5.17x 4.3x 3.63x
PEG - 0.5x 3.51x 2x -0x 1.8x 1.8x 1.2x
Capitalization / Revenue 7.37x 8.3x 10.6x 9.41x 9.58x 8.77x 8.01x 7.22x
EV / Revenue 6.38x 7.09x 9.49x 8.86x 9.03x 7.79x 6.81x 5.86x
EV / EBITDA 10.8x 12.8x 20.6x 108x 19.8x 17.6x 14.6x 12.2x
EV / EBIT 11.1x 13.2x 21.4x 140x 20.6x 18.3x 15.4x 12.7x
EV / FCF 20.1x 16.1x 28.1x -123x 33.9x 20.9x 18.9x 16.4x
FCF Yield 4.99% 6.2% 3.56% -0.81% 2.95% 4.78% 5.29% 6.08%
Dividend per Share 2 - - - - - - - -
Rate of return - - - - - - - -
EPS 2 9.01 12.82 13.89 -2.08 15.32 17.49 19.71 23.03
Distribution rate - - - - - - - -
Net sales 1 7,574 8,931 9,869 11,020 12,001 13,038 14,267 15,840
EBITDA 1 4,470 4,941 4,556 902.8 5,473 5,782 6,651 7,618
EBIT 1 4,344 4,793 4,375 695.6 5,263 5,554 6,319 7,333
Net income 1 2,342 3,322 3,620 -535.6 3,953 4,451 5,053 5,979
Net Debt 1 -7,525 -10,778 -11,218 -6,116 -6,608 -12,785 -17,134 -21,501
Reference price 2 219.60 288.78 406.89 402.70 453.36 450.46 450.46 450.46
Nbr of stocks (in thousands) 254,252 256,691 257,683 257,529 253,719 253,805 - -
Announcement Date 26/1/22 7/2/23 5/2/24 10/2/25 12/2/26 - - -
1USD in Million2USD
Estimates

P/E Ratio, Detailed evolution

P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
25.76x7.79x17.56x-.--% 114B
33.05x12.01x24.74x0.6% 1,007B
25.19x5.81x15.79x2.26% 567B
27.13x6.62x13.53x3.1% 392B
17.5x4.32x10.61x3.07% 328B
20.98x5.43x13.17x2.95% 277B
22.23x4.65x13.18x1.88% 275B
12.63x4.73x9.67x3.97% 196B
22.79x6.1x10.65x2.88% 189B
-44.54x5.38x29.66x2.61% 154B
Average 16.27x 6.28x 15.86x 2.33% 350.04B
Weighted average by Cap. 22.49x 7.42x 17.26x 2.05%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA

Year-on-year evolution of the Yield

  1. Stock Market
  2. Stocks
  3. VRTX Stock
  4. Valuation Vertex Pharmaceuticals Incorporated
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!